Atlas Trials

Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma

Clinical trial NCT07388758 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07388758
Sponsor
Sun Yat-sen University
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Nasopharyngeal Carcinoma (NPC)
Start date
2026-02-01
Primary completion
2028-02-01
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.